Arbutus Biopharma Corp (ABUS) bonds

ABUSNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 12/3082% below fair value

$4.03+0.15 (+3.87%)

Close on Nov 12, 2026Market cap $797.33MP/E 3.6Yield –

Debt

Borrowings on the balance sheet, Sep 30, 2026

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

Individual notes, bonds and loans

The debt footnote in the annual report has no machine-readable detail for individual notes, so coupons and maturities cannot be listed.

Parsed from the XBRL in Arbutus Biopharma's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-5 reverse split on Nov 4, 2010
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ABUS.

Revenue growth1142.6% · median 23.3%

Operating margin81.1% · median -72.7%

Net margin121.2% · median -58.8%

Advertisement
300 × 250

See a number that looks wrong?